Industrial studies

Deferiprone ApoPharma SKY II A Dose-Ranging Study of the Efficacy, Safety, and Pharmacokinetics of Deferiprone Delayed Release Tablets in Patients with Parkinson’s Disease

PXT002331 PREXTON AMBLED IIa A Multi-centre, Double-blind, Randomised, Placebo-controlled, Parallel-arm Phase IIa Trial to Evaluate the Efficacy, Safety and Tolerability of 28-Day Oral Treatment with PXT002331 (foliglurax) in Reducing Motor Complications of Levodopa Therapy in Subjects with Parkinson’s Disease Experiencing End-of-dose Wearing Off and Levodopa-Induced Dyskinesia
Apomorphine / device ORKYN OPTIPARK 2.0 NA

Use an Actimetry procedure during initiation of treatment with apomorphine delivered by a pump in patients with Parkinson's disease

R07046015 ROCHE PASADENA II A randomized, double-blind, placebo controlled, 52-week phase II study to evaluate the efficacy of intravenous RO7046015 (PRX002) in participants with early Parkinson's disease with a 52 week blinded extension
BIIB092  BIOGEN PASSPORT II A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants with Progressive Supranuclear Palsy
ABBV-8E12  ABBVIE ARISE II A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy
IPT803 TOOLS4PATIENT   POC A Proof of Concept Study to Investigate the Effect of IPT803 Adjunct Treatment in Patients with Parkinson’s Disease.